Icatibant (Firazyr)

FDA-approved product existsPeptideImmune & gut

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Icatibant (Firazyr)?

FDA-approved icatibant is marketed as Firazyr for treatment of acute hereditary angioedema attacks in adults 18 years and older.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelFIRAZYR prescribing information for acute hereditary-angioedema attacks
PopulationAdults covered by the approved FIRAZYR indication
Dose30 mg; if response is inadequate or symptoms recur, additional 30 mg injections may be given at intervals of at least 6 hours, with no more than 3 injections in 24 hours.
RouteSubcutaneous injection in the abdominal area
FrequencyPer acute attack, with label-defined repeat-dose limits
DurationSingle-attack use
PreparationReady-to-use 30 mg/3 mL single-dose prefilled syringe; no reconstitution.
Source: Dosage and Administration sections 2.1-2.2; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.